Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects - Taskinen, Marja-Riitta; Björnson, Elias; Andersson, Linda; Kahri, Juhani; Porthan, Kimmo; Matikainen, Niina; Söderlund, Sanni; Pietiläinen, Kirsi; Hakkarainen, Antti; Lundbom, Nina; Nilsson, Ralf; Ståhlman, Marcus; et al. (Journal of clinical lipidology, 2020)
Keywords: apoB; Apolipoprotein C3; Atherogenic dyslipidemia; atherosclerotic cardiovascular-disease; atorvastatin; bile-acid; Cell and Molecular Biology; Cell- och molekylärbiologi; cholesterol; De novo lipogenesis; Evolocumab; Farmakologi och toxikologi; fat; fat-content; hmg-coa reductase; hypertriglyceridemia; Liver; Liver fat; metabolism; PCSK9; Pharmacology & Pharmacy; Pharmacology and Toxicology; Postprandial lipids; precursors; Remnant lipoproteins; risk-factor; stable-isotope; Remnant lipoproteins; Apolipoprotein C3; Atherogenic dyslipidemia; Postprandial lipids; Liver fat; Evolocumab; De novo lipogenesis; PCSK9; apoB